Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Introduction
Featured Profiles
Genmab
Geron
SpringWorks
Special Series
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Conference Correspondent
DLBCL Download: Emerging Insights From ASCO 2026
ESMO 2025 - Early Breast Cancer
Evolving Landscapes in Multiple Myeloma
OFS Summit
Multimedia
All Videos
Cancer, Clearly
Case-Based Exchanges
Voices From ASCO 2025
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Quick Quiz
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Introduction
Featured Profiles
Genmab
Geron
SpringWorks
Special Series
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Conference Correspondent
DLBCL Download: Emerging Insights From ASCO 2026
ESMO 2025 - Early Breast Cancer
Evolving Landscapes in Multiple Myeloma
OFS Summit
Multimedia
All Videos
Cancer, Clearly
Case-Based Exchanges
Voices From ASCO 2025
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Quick Quiz
Subscribe
FDA Approvals, News & Updates
Venclexta Indicated for CLL or SLL, Alone or in Combination with Rituxan
FDA Approvals, News & Updates
August 2018, Vol 8, No 8
Read More ›
Keytruda Receives 2 New Indications: Metastatic Cervical Cancer and Relapsed Mediastinal Large B-Cell Lymphoma
FDA Approvals, News & Updates
August 2018, Vol 8, No 8
Read More ›
Bevacizumab plus Chemotherapy Approved for Several Types of Ovarian Cancer
FDA Approvals, News & Updates
August 2018, Vol 8, No 8
Read More ›
FDA Approves 2 New Biosimilars for Patients with Cancer
FDA Approvals, News & Updates
August 2018, Vol 8, No 8
Read More ›
Verzenio Receives New Indication as Initial Treatment for Metastatic Breast Cancer
FDA Approvals, News & Updates
,
Breast Cancer
,
Breast Cancer
May 2018, Vol 8, No 5
Read More ›
Blincyto Approved for Patients with B-Cell ALL and Minimal Residual Disease
FDA Approvals, News & Updates
May 2018, Vol 8, No 5
Read More ›
Adcetris Approved as Initial Treatment for Stage III or IV Classical Hodgkin Lymphoma
FDA Approvals, News & Updates
May 2018, Vol 8, No 5
Read More ›
Rubraca Approved as Maintenance Treatment for Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
FDA Approvals, News & Updates
May 2018, Vol 8, No 5
Read More ›
Tagrisso Now Approved as First-Line Therapy for Patients with Metastatic NSCLC and EGFR Mutations
FDA Approvals, News & Updates
May 2018, Vol 8, No 5
Read More ›
Zejula (Niraparib) First PARP Inhibitor Approved for Maintenance Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
By
Lisa A. Raedler, PhD, RPh
FDA Approvals, News & Updates
2018 Third Annual Oncology Guide to New FDA Approvals
Read More ›
Page 33 of 38
30
31
32
33
34
35
36
